Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trialDouglas R. Adkins, Peter Oppelt, Jessica Ley et al.|The Lancet Oncology|2019Cited by 125
Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trialPeter Oppelt, Douglas R. Adkins, Jessica Ley et al.|Oral Oncology|2021Cited by 21
Multicenter phase II trial of palbociclib, a selective cyclin dependent kinase (CDK) 4/6 inhibitor, and cetuximab in platinum-resistant HPV unrelated (-) recurrent/metastatic head and neck squamous cell carcinoma (RM HNSCC).Douglas R. Adkins, Nabil F. Saba, Jessica Ley et al.|Journal of Clinical Oncology|2018Cited by 17
Polypharmacy, potentially inappropriate medications, and chemotherapy-related adverse events among older adults with cancer.Ronald J. Maggiore, Arti Hurria, Vani Katheria et al.|Journal of Clinical Oncology|2011Cited by 11
Measures of polypharmacy and chemotherapy toxicity in older adults with cancer.Ronald J. Maggiore, Arti Hurria, Tao Feng et al.|Journal of Clinical Oncology|2013Cited by 7